|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowances | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use asset, net | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Deferred financing costs | ||||||||||||||||||||
| In-process research and development, net of accumulated amortization | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total Other Assets | ||||||||||||||||||||
| Total Other Assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| License payable | ||||||||||||||||||||
| License payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Note payable | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Notes payable, net of deferred financing fees | ||||||||||||||||||||
| Operating lease liability – noncurrent | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Common stock - $0.001 par value; 250,000,000 shares authorized; 27,452,570 and 18,067,744 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Citius Pharmaceuticals, Inc. Stockholders’ Equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total Equity | ||||||||||||||||||||
| Total Liabilities and Equity |
Loading...
